Stereotaxis, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Stereotaxis, Inc. on February 27, 2009. The report addresses a significant regulatory milestone involving the company's NIOBE Magnetic Navigation System and its partnership with Biosense Webster, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate event rather than financial performance data.
Material Changes
On February 27, 2009, the U.S. Food and Drug Administration (FDA) approved the marketing of the NAVISTAR RMT THERMOCOOL Catheter for use with the Stereotaxis NIOBE platform. This catheter, developed in partnership with Biosense Webster, Inc., is designed for radiofrequency (RF) ablation. The NIOBE system facilitates the remote steering of the catheter to guide ablation to targeted treatment areas.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the context of the FDA approval. The primary focus is the successful regulatory clearance of the partnered device.
Investor Verification Points
- Confirm the commercial launch timeline for the NAVISTAR RMT THERMOCOOL Catheter following FDA approval.
- Review the terms of the partnership agreement between Stereotaxis and Biosense Webster regarding revenue sharing or royalties.
- Assess the potential market impact of the NIOBE platform's expanded catheter compatibility on future sales.